146 related articles for article (PubMed ID: 20834238)
21. The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers.
Shimada S; Ishizawa T; Ishizawa K; Matsumura T; Hasegawa T; Hirose T
Hum Pathol; 2006 Sep; 37(9):1123-9. PubMed ID: 16938516
[TBL] [Abstract][Full Text] [Related]
22. Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas.
Horvai AE; Schaefer JT; Nakakura EK; O'Donnell RJ
Mod Pathol; 2008 May; 21(5):517-24. PubMed ID: 18204431
[TBL] [Abstract][Full Text] [Related]
23. Lipomatous tumors.
Weiss SW
Monogr Pathol; 1996; 38():207-39. PubMed ID: 8744279
[TBL] [Abstract][Full Text] [Related]
24. HMGA2 is a sensitive but not specific immunohistochemical marker of vulvovaginal aggressive angiomyxoma.
McCluggage WG; Connolly L; McBride HA
Am J Surg Pathol; 2010 Jul; 34(7):1037-42. PubMed ID: 20551826
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas.
Hostein I; Pelmus M; Aurias A; Pedeutour F; Mathoulin-Pélissier S; Coindre JM
J Pathol; 2004 Jan; 202(1):95-102. PubMed ID: 14694526
[TBL] [Abstract][Full Text] [Related]
26. Myolipoma of Soft Tissue: Clinicopathologic Analysis of 34 Cases.
Fukushima M; Schaefer IM; Fletcher CD
Am J Surg Pathol; 2017 Feb; 41(2):153-160. PubMed ID: 27635945
[TBL] [Abstract][Full Text] [Related]
27. Aggressive angiomyxoma [corrected] of the female genital tract and pelvis--clinicopathologic features with immunohistochemical analysis.
Bigby SM; Symmans PJ; Miller MV; Dray MS; Jones RW
Int J Gynecol Pathol; 2011 Sep; 30(5):505-13. PubMed ID: 21804399
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
Li N; McNiff J; Hui P; Manfioletti G; Tallini G
Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
[TBL] [Abstract][Full Text] [Related]
29. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity.
Coindre JM; Hostein I; Maire G; Derré J; Guillou L; Leroux A; Ghnassia JP; Collin F; Pedeutour F; Aurias A
J Pathol; 2004 Jul; 203(3):822-30. PubMed ID: 15221942
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias.
Belge G; Meyer A; Klemke M; Burchardt K; Stern C; Wosniok W; Loeschke S; Bullerdiek J
Genes Chromosomes Cancer; 2008 Jan; 47(1):56-63. PubMed ID: 17943974
[TBL] [Abstract][Full Text] [Related]
31. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics.
Doyle LA; Vivero M; Fletcher CD; Mertens F; Hornick JL
Mod Pathol; 2014 Mar; 27(3):390-5. PubMed ID: 24030747
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of the MDM2/HMGA2 ratio and histological tumor grade in dedifferentiated liposarcoma.
Yamashita K; Kohashi K; Yamada Y; Akatsuka S; Ikuta K; Nishida Y; Toyokuni S; Oda Y
Genes Chromosomes Cancer; 2021 Jan; 60(1):26-37. PubMed ID: 33111425
[TBL] [Abstract][Full Text] [Related]
33. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma.
Coindre JM; Mariani O; Chibon F; Mairal A; De Saint Aubain Somerhausen N; Favre-Guillevin E; Bui NB; Stoeckle E; Hostein I; Aurias A
Mod Pathol; 2003 Mar; 16(3):256-62. PubMed ID: 12640106
[TBL] [Abstract][Full Text] [Related]
34. MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors.
Nakayama T; Toguchida J; Wadayama B; Kanoe H; Kotoura Y; Sasaki MS
Int J Cancer; 1995 Oct; 64(5):342-6. PubMed ID: 7591308
[TBL] [Abstract][Full Text] [Related]
35. HMGA2 Is a Useful Marker of Vulvovaginal Aggressive Angiomyxoma But May Be Positive in Other Mesenchymal Lesions at This Site.
Harkness R; McCluggage WG
Int J Gynecol Pathol; 2021 Mar; 40(2):185-189. PubMed ID: 32897956
[TBL] [Abstract][Full Text] [Related]
36. Misexpression of full-length HMGA2 induces benign mesenchymal tumors in mice.
Zaidi MR; Okada Y; Chada KK
Cancer Res; 2006 Aug; 66(15):7453-9. PubMed ID: 16885341
[TBL] [Abstract][Full Text] [Related]
37. HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma.
Hristov AC; Cope L; Reyes MD; Singh M; Iacobuzio-Donahue C; Maitra A; Resar LM
Mod Pathol; 2009 Jan; 22(1):43-9. PubMed ID: 18843278
[TBL] [Abstract][Full Text] [Related]
38. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.
Italiano A; Bianchini L; Keslair F; Bonnafous S; Cardot-Leccia N; Coindre JM; Dumollard JM; Hofman P; Leroux A; Mainguené C; Peyrottes I; Ranchere-Vince D; Terrier P; Tran A; Gual P; Pedeutour F
Int J Cancer; 2008 May; 122(10):2233-41. PubMed ID: 18214854
[TBL] [Abstract][Full Text] [Related]
39. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours.
Aleixo PB; Hartmann AA; Menezes IC; Meurer RT; Oliveira AM
J Clin Pathol; 2009 Dec; 62(12):1127-35. PubMed ID: 19946100
[TBL] [Abstract][Full Text] [Related]
40. [From cytogenetics to cytogenomics of adipose tissue tumors: 2. Malignant adipose tissue tumors].
Pedeutour F; Maire G; Sirvent N;
Bull Cancer; 2004 Apr; 91(4):317-23. PubMed ID: 15242313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
